Advertisement
Table 1 Univariate analysis for clinical characteristics of patients infected or colonized with RPKP and RNKP isolates
| Characteristics | Patients with RPKP (n = 35) | Patients with RNKP (n = 29) | P value |
|---|---|---|---|
| Male sex | 28(80.0) | 21(72.4) | 0.79 |
| Age, mean years ± SD | 63 ± 13.8 | 63 ± 18.9 | 0.988 |
| Ward | |||
| ICU | 17(48.6) | 17(58.6) | 0.68 |
| Medicine | 6(17.1) | 2(6.9) | 0.45 |
| Surgery | 12(34.3) | 10(34.5) | >0.99 |
| Transferred from another hospital | 15(42.9) | 13(44.8) | 0.92 |
| Total length of stay in any hospital before isolation of KPC-KP, | |||
| mean days ± SD | 18.7 ± 15.1 | 16.2 ± 15.0 | 0.525 |
| Total length of stay until discharge or death, mean days ± SD | 36.1 ± 22.2 | 35.6 ± 22.4 | 0.94 |
| Route of acquisition of KPC-KP | 0.203 | ||
| Imported | 4(11.4) | 7(24.1) | -- |
| Acquired in our hospital | 31(88.6) | 22(75.9) | -- |
| Site of KPC-KP isolation | |||
| Bronchial secretion | 15(42.9) | 12(41.4) | >0.99 |
| Blood | 6(17.1) | 10(34.5) | 0.27 |
| Drainage | 7(20.0) | 6(20.7) | >0.99 |
| Urine | 4(11.4) | 1(3.4) | 0.38 |
| Cerebrospinal fluid | 2(5.7) | 0 | -- |
| Pus | 1(2.9) | 0 | -- |
| Infection | 31(88.6) | 28(96.6) | 0.37 |
| Median APACHEII score | 17(2–37) | 16(2–35) | 0.129 |
| Median Charlson score | 2(0–10) | 2(0–5) | 0.233 |
| Invasive procedures | |||
| Surgery within a month | 16(45.7) | 15(51.7) | 0.83 |
| Mechanical ventilation | 18(51.4) | 18(62.1) | 0.68 |
| Renal replacement therapy | 11(31.4) | 9(31.0) | >0.99 |
| Drainage catheters | 33(94.3) | 20(68.9) | 0.46 |
| Total times of bed transfer during this hospitalization, mean times ± SD | 2.54 ± 1.31 | 2.52 ± 1.38 | 0.94 |
| Total times of bed transfer after KPC-KP isolation, mean times ± SD | 1.57 ± 0.95 | 1.66 ± 0.94 | 0.72 |
| Antibiotic therapy during the last month | |||
| Piperacillin-tazobactam | 6(17.1) | 5(17.2) | >0.99 |
| Third-generation cephalosporins | 21(60.0) | 21(72.4) | 0.69 |
| Carbapenems | 21(60.0) | 13(44.8) | 0.53 |
| Quinolones | 10(28.6) | 3(10.3) | 0.22 |
| Fosfomycin | 2(5.7) | 1(3.4) | >0.99 |
| Aminoglycosides | 0 | 1(3.4) | -- |
| Minocycline | 1(2.9) | 0 | -- |
| Crude mortality | 8(22.9) | 8(27.6) | 0.77 |
| Attributable mortality | 6(19.4)a | 5(17.9) | 0.88 |
